In a critical move to curb the spread of the Bundibugyo ebolavirus (BDBV) currently impacting the Democratic Republic of the Congo (DRC) and Uganda, the Coalition for Epidemic Preparedness Innovations (CEPI) has announced a high-priority, fast-tracked development program for three investigational vaccine candidates. The initiative marks a turning point in the battle against this specific, rare strain of the virus, for which no licensed vaccine or established clinical pathway currently exists.
Following extensive global consultations with the World Health Organization (WHO), the Africa Centres for Disease Control and Prevention (Africa CDC), and other international health stakeholders, CEPI has selected candidates from IAVI, Moderna, and the University of Oxford. This tripartite approach leverages a diverse range of vaccine platforms, including recombinant viral vectors and mRNA technology, to maximize the probability of identifying a successful, scalable solution.
The Urgency of the BDBV Threat
Bundibugyo ebolavirus is a member of the Ebolavirus genus, known for its high fatality rates and capacity to cause widespread panic in underserved regions. Historically, BDBV has been considered rare, with only two significant documented outbreaks prior to the current crisis. However, the lack of medical countermeasures for this specific strain renders it a formidable public health challenge.
"With the Bundibugyo virus spreading rapidly and no licensed vaccines, every day counts in the race against this deadly disease," stated Richard Hatchett, CEO of CEPI. "CEPI’s urgent funding and support for these three promising candidates aims to advance safe, effective vaccines to help control this epidemic and prevent future, more devastating outbreaks."
Chronology of Development and Strategic Selection
The selection of these three candidates is the result of a rigorous evaluation process that prioritized speed, technical feasibility, and the potential for rapid manufacturing.
IAVI: The rVSV Approach
IAVI’s candidate, originally pioneered at The University of Texas Medical Branch, utilizes a recombinant vesicular stomatitis virus (rVSV) platform. This technology is already validated; it is the backbone of the only currently licensed vaccine for the Zaire ebolavirus and was effectively deployed during the 2025 Sudan virus outbreak in Uganda.
CEPI has committed $3.2 million to this program. The funding is earmarked for the generation of a Master Virus Seed stock and the critical transfer of manufacturing processes to a contract development and manufacturing organization (CDMO) capable of Good Manufacturing Practice (GMP) production. While the vaccine has shown strong efficacy in non-human primate models, it remains untested in human populations, making its clinical trajectory a primary focus for the WHO.
Moderna: Leveraging mRNA Versatility
Moderna’s inclusion represents a strategic pivot toward mRNA technology—the same platform that revolutionized the global response to COVID-19. CEPI has pledged up to $50 million for this candidate, covering the comprehensive spectrum of preclinical testing, Phase 1 clinical trials, and concurrent manufacturing setup. This "parallel-track" strategy is designed to enable a seamless transition into Phase 2 and 3 efficacy trials should the initial safety data prove positive.
The University of Oxford: ChAdOx1 Platform
The University of Oxford brings its ChAdOx1 viral vector platform to the table, a technology that gained global prominence as the foundation for the AstraZeneca COVID-19 vaccine. With an investment of $8.6 million, CEPI is supporting Oxford in the preclinical evaluation, creation of a Master Virus Seed stock, and the production of clinical-grade vaccine doses. This platform has previously demonstrated promise against other filoviruses, including the Zaire ebolavirus, Sudan virus, and Marburg virus, providing a strong scientific basis for its application against BDBV.
Supporting Data: The Financial and Scientific Landscape
The financial commitment by CEPI occurs against a backdrop of shifting priorities in the biotechnology sector. For companies like Moderna, the BDBV program represents both a humanitarian commitment and a scientific opportunity.
The Financial Climate for Moderna
Moderna’s financial position has been characterized by recent volatility. Following a 30% year-over-year revenue decline in the fourth quarter of 2025, the company reported $0.4 billion in revenue for the first quarter of 2026, with the vast majority (80%) sourced from international markets. In the preceding year, Moderna invested $3.1 billion in research and development against $1.9 billion in revenue, highlighting the high-risk nature of their pipeline.
By backing this program, CEPI is effectively de-risking a project that is commercially unviable due to the localized nature of the outbreak and the rarity of the BDBV strain. For Moderna, this grant provides a pathway to continue validating its mRNA platform for filoviruses while accumulating clinical data that would otherwise be difficult to justify under current market pressures.
The Geopolitical Context of mRNA Research
The CEPI investment arrives at a time of significant policy upheaval in the United States. In August 2025, the U.S. government took the controversial step of terminating 22 federal contracts related to mRNA vaccine development, effectively winding down substantial federal support for the platform. By filling the vacuum left by the withdrawal of public sector funding, CEPI is positioning itself as the primary financier for next-generation vaccine research that would otherwise be abandoned.
Official Responses and Collaborative Frameworks
The response to the BDBV epidemic is defined by an unprecedented level of institutional cooperation. CEPI is not acting in isolation; the organization is working closely with Gavi, the Vaccine Alliance, the World Bank, and various development finance institutions. This collaboration is essential to create "surge financing" mechanisms, ensuring that should any of the three candidates succeed in clinical trials, the funding for large-scale procurement and global distribution is already secured.
"We will move with urgency and scientific rigor to support the response and help bring a potential vaccine closer to the communities that need it most," noted Stephane Bancel, CEO of Moderna.
The WHO and Africa CDC remain the central coordinators for clinical trial sites in the DRC and Uganda, ensuring that the research conducted adheres to international ethical standards while respecting the sovereignty and needs of the affected nations.
Implications for Future Epidemic Preparedness
The fast-tracking of these vaccines has profound implications for global health security.
1. Proof of the "Platform" Strategy
By testing three distinct platforms (rVSV, mRNA, and ChAdOx1) simultaneously, CEPI is testing the hypothesis that platform-based technology—rather than pathogen-specific development—is the key to future epidemic response. If one or more of these candidates succeeds, it will validate the ability to rapidly "plug and play" viral antigens into existing, safe delivery vectors.
2. Addressing "Neglected" Pathogens
The Bundibugyo strain has historically been neglected by the pharmaceutical industry due to the low profit potential of vaccines for rare, sporadic outbreaks. This initiative demonstrates that international coalitions can effectively bridge the "market failure" gap, ensuring that health equity is prioritized even when profit margins are non-existent.
3. The Shift in Global Funding
With the U.S. government retreating from broad mRNA research, organizations like CEPI are becoming the de facto curators of global vaccine innovation. This transition suggests a shift toward a multi-stakeholder funding model, where international NGOs, regional health bodies, and development banks assume the role previously held by national governments.
Moving Forward: Continuous Evaluation
The work is far from complete. CEPI has stated that it will continue to monitor the situation on the ground and is maintaining an open call for proposals to identify additional candidates that may offer superior efficacy or easier logistical deployment in remote, resource-limited settings.
As clinical trials begin, the global scientific community remains vigilant. The success of these trials would not only provide a life-saving tool for the people of the DRC and Uganda but would also mark a major milestone in the evolution of vaccine science, proving that with adequate, targeted investment, the world can move from a reactive posture to a proactive defense against the next generation of viral threats.
For now, the eyes of the international health community are on the clinical sites in Central Africa, where the race to validate these three candidates represents the best hope for containing an epidemic that threatens to grow beyond control. Through scientific rigor, international solidarity, and sustained financial commitment, the hope is that this effort will serve as a blueprint for how the world manages the inevitable outbreaks of the future.
About the Author
